Pancreatic Cancer Research

ResearcherGunma UniversityActive in the last 2 years

Norihiro Ishii

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6591-2439; OpenAlex author ID A5062177342. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 11

  1. CD86-Positive Mature Tertiary Lymphoid Structures Are Associated With CD8+ T-Cell Infiltration and Favorable Clinical Outcomes in Pancreatic Ductal Adenocarcin… Co-author DOI 10.1002/ags3.70275↗
  2. Potential of Mac-2-binding protein glycan isomer as a new therapeutic target in pancreatic cancer. Co-author DOI 10.1111/cas.16087↗
  3. Usefulness of serum creatinine and cystatin C ratio as a screening tool for predicting prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/ags3.12671↗
  4. High RRN3 expression is associated with malignant characteristics and poor prognosis in pancreatic cancer. First author DOI 10.1007/s10147-023-02342-w↗
  5. Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World St… Co-author DOI 10.1159/000525742↗
  6. D-Dimer Could Be a Surrogate Postoperative Prognostic Marker of Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001537↗
  7. High Co-expression of Large Tenascin C Splice Variants in Stromal Tissue and Annexin A2 in Cancer Cell Membranes is Associated with Poor Prognosis in Pancreati… Co-author DOI 10.1245/s10434-019-07708-x↗
  8. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Co-author DOI 10.1111/cas.13847↗
  9. High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Clinical Patients with Pancreatic Cancer. Co-author DOI 10.21873/anticanres.12307↗
  10. Association of RAB5 overexpression in pancreatic cancer with cancer progression and poor prognosis via E-cadherin suppression. Co-author DOI 10.18632/oncotarget.14703↗
  11. Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1. Co-author DOI 10.18632/oncotarget.22634↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Araki · 11 shared papers, 2017–2026 · strength 1.36
  2. Ken Shirabe · 11 shared papers, 2017–2026 · strength 1.36
  3. Mariko Tsukagoshi · 10 shared papers, 2017–2026 · strength 1.24
  4. Akira Watanabe · 9 shared papers, 2017–2024 · strength 0.96
  5. Takehiko Yokobori · 8 shared papers, 2017–2026 · strength 0.96
  6. Kei Hagiwara · 7 shared papers, 2018–2024 · strength 0.84
  7. Norifumi Harimoto · 7 shared papers, 2018–2024 · strength 0.84
  8. Takahiro Yamanaka · 8 shared papers, 2017–2024 · strength 0.78
  9. Takamichi Igarashi · 7 shared papers, 2017–2026 · strength 0.74
  10. Takaomi Seki · 1 shared paper, 2026 · strength 0.28
  11. Hiroyuki Kuwano · 4 shared papers, 2017–2019 · strength 0.26
  12. Atsushi Masamune · 2 shared papers, 2019–2024 · strength 0.26
  13. Kiyoaki Ito · 1 shared paper, 2024 · strength 0.18
  14. Chingunjav Batbayar · 1 shared paper, 2023 · strength 0.15
  15. Hidetoshi Yasuoka · 1 shared paper, 2022 · strength 0.12
  16. Takashi Hoshino · 1 shared paper, 2022 · strength 0.12
  17. Satoru Kakizaki · 1 shared paper, 2022 · strength 0.12
  18. Bolag Altan · 2 shared papers, 2017 · strength 0.12
  19. Kazunobu Suzuki · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.